KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Convertible Debt (2016 - 2025)

Historic Convertible Debt for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $596.7 million.

  • Biomarin Pharmaceutical's Convertible Debt rose 34.24% to $596.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $596.7 million, marking a year-over-year increase of 34.24%. This contributed to the annual value of $595.1 million for FY2024, which is 4524.81% down from last year.
  • Biomarin Pharmaceutical's Convertible Debt amounted to $596.7 million in Q3 2025, which was up 34.24% from $596.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Convertible Debt high stood at $1.1 billion for Q2 2024, and its period low was $594.6 million during Q3 2024.
  • For the 5-year period, Biomarin Pharmaceutical's Convertible Debt averaged around $954.4 million, with its median value being $1.1 billion (2022).
  • Its Convertible Debt has fluctuated over the past 5 years, first surged by 2620.57% in 2021, then crashed by 4525.37% in 2025.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Convertible Debt stood at $1.1 billion in 2021, then rose by 0.37% to $1.1 billion in 2022, then grew by 0.36% to $1.1 billion in 2023, then tumbled by 45.25% to $595.1 million in 2024, then increased by 0.26% to $596.7 million in 2025.
  • Its last three reported values are $596.7 million in Q3 2025, $596.2 million for Q2 2025, and $595.6 million during Q1 2025.